Previous 10 | Next 10 |
HQH offers investors a managed quarterly distribution based on 2% of the NAV. The fund's discount has been tightening lately, but is still attractive for long-term investors. The healthcare exposure provides for a mixture of recession-resistant investments that worked especially w...
Horizon Therapeutics ([[HZNP]] -1.4%) sees interim FY20 revenues of $2.12B-2.14B; exceeding the high end of the guidance range of $2.13B and representing more than 65% Y/Y growth, driven by strong net sales from its two key growth drivers, TEPEZZA, its biologic for the treatment of Thyro...
- Company to present at 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021 at 11:40 a.m. ET - Horizon Therapeutics plc (Nasdaq: HZNP) today announced updates on its 2020 financial results, TEPEZZA supply and new KRYSTEXXA trials. “Amid th...
Horizon Therapeutics has morphed into a biotech star due to its new compound Tepezza. Tepezza is approved for the treatment of thyroid eye disease otherwise known as TED. Tepezza is a star generating faster growth as widespread adoption has occurred at a pace faster than expected....
Selecta was down due to unclear results from the COMPARE trial. Management attributes poor data to noncompliance due to covid-19, among other things. Their ImmTOR platform makes it highly interesting. For further details see: Selecta: ImmTOR Platform's Potential In Key ...
Horizon Therapeutics ([[HZNP]] -9.7%) says it expects a short-term disruption in Tepezza supplies that will begin at the end of December and could last through the first quarter of 2021, due to COVID-19 vaccine production orders that have dramatically restricted capacity available for th...
- Conference Call Today at 8 a.m. ET - Horizon Therapeutics plc (Nasdaq: HZNP) announced that it expects a short-term disruption in TEPEZZA (teprotumumab-trbw) supply as a result of recent government-mandated COVID-19 vaccine production orders related to Operation Warp Speed...
Halvorsen's 13F portfolio value increased from $23.14B to $27.68B. The number of positions increased 71 to 86. Viking Global increased Microsoft, Mecadolibre, and CME Group while reducing Amazon.com and dropping Uber Technologies & JD.com. The top three positions are Microsoft...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has provided $500,000 in scholarships to Lake Forest College and created a $500,000 Horizon Therapeutics Endowed Scholarship Fund at Howard University . The scholarships at both institutions will be awarded to econo...
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has been named to Great Place to Work’s 2020 Best Workplaces for Parents list, which highlights companies that have created consistently positive experiences for working parents, especially in light of the COVID-...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...